Baker Ellis Asset Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$235K Hold
1,200
0.03% 231
2025
Q4
$208K Hold
1,200
0.03% 247
2025
Q3
$229K Hold
1,200
0.03% 227
2025
Q2
$216K Sell
1,200
-20
-2% -$3.47K 0.03% 203
2025
Q1
$206K Buy
+1,220
New +$200K 0.03% 207
2023
Q1
Sell
-1,300
Closed -$203K 212
2022
Q4
$203K Buy
+1,300
New +$187K 0.04% 193
2022
Q1
Sell
-1,300
Closed -$225K 213
2021
Q4
$225K Buy
+1,300
New +$198K 0.04% 196
2020
Q3
Sell
-1,400
Closed -$160K 174
2020
Q2
$160K Hold
1,400
0.05% 166
2020
Q1
$112K Sell
1,400
-200
-13% -$20.7K 0.04% 166
2019
Q4
$171K Hold
1,600
0.05% 170
2019
Q3
$171K Hold
1,600
0.05% 185
2019
Q2
$163K Hold
1,600
0.04% 187
2019
Q1
$144K Sell
1,600
-100
-6% -$8.66K 0.04% 185
2018
Q4
$142K Hold
1,700
0.04% 180
2018
Q3
$183K Hold
1,700
0.05% 188
2018
Q2
$187K Hold
1,700
0.05% 187
2018
Q1
$171K Sell
1,700
-100
-6% -$10.2K 0.04% 189
2017
Q4
$177K Sell
1,800
-450
-20% -$42.7K 0.04% 191
2017
Q3
$211K Hold
2,250
0.06% 185
2017
Q2
$250K Hold
2,250
0.07% 180
2017
Q1
$221K Hold
2,250
0.06% 185
2016
Q4
$207K Buy
2,250
+100
+5% +$8.62K 0.06% 188
2016
Q3
$182K Hold
2,150
0.05% 196
2016
Q2
$175K Hold
2,150
0.05% 194
2016
Q1
$154K Sell
2,150
-100
-4% -$6.71K 0.05% 202
2015
Q4
$160K Hold
2,250
0.05% 202
2015
Q3
$138K Sell
2,250
-100
-4% -$6.99K 0.05% 218
2015
Q2
$170K Hold
2,350
0.06% 211
2015
Q1
$181K Buy
+2,350
New +$168K 0.06% 209
2013
Q3
Sell
-2,700
Closed -$164K 244
2013
Q2
$164K Buy
+2,700
New +$161K 0.07% 208

Other funds holding DGX

Baker Ellis Asset Management's DGX Position: Q1 2026 in Review

Baker Ellis Asset Management held its Quest Diagnostics (DGX) position steady in Q1 2026 at 1,200 shares worth $235K. The position accounts for 0.03% of the portfolio, ranked #231.

Baker Ellis Asset Management first reported a position in DGX in Q2 2013 and has held it in 30 quarters since. The position peaked at $250K in Q2 2017. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Baker Ellis Asset Management held 1,200 shares of Quest Diagnostics worth $235K as of Q1 2026.
  • Baker Ellis Asset Management left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up 0.03% of Baker Ellis Asset Management's portfolio in Q1 2026, its #231 holding.
  • Baker Ellis Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 30 quarters since.
  • Baker Ellis Asset Management's Quest Diagnostics position peaked at $250K in Q2 2017.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Baker Ellis Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.